U.S. Health Care REITs Stock News

Black Hills (BKH) is drawing fresh attention after recent trading left the stock down about 6% over the past week and roughly 10% over the past month, which has sharpened the focus on its utility-driven fundamentals. See our latest analysis for Black Hills. At a share price of $67.78, Black Hills has seen its recent share price momentum fade, with the stock down 5.9% over the past week and 9.9% over the past month, even as its 1 year total shareholder return sits at 22.3%. If this shift in...

In recent days, ProFrac Holding was swept up in sharp swings across energy stocks as direct military actions between Israel and Iran, and subsequent US comments on a possible response over the Strait of Hormuz, heightened and then partially eased geopolitical risk concerns for the oil and gas sector. This turmoil underscored how ProFrac’s fortunes can be influenced less by its own operations and more by shifting expectations around global supply security and demand for energy services amid...

In recent weeks, Arcus Biosciences announced a clinical trial collaboration with Bristol Myers Squibb to add its HIF-2a inhibitor casdatifan to the BMS-sponsored ROSETTA RCC-208 trial in advanced renal cell carcinoma, while regulators accepted a Priority Review for Camzyos in adolescent obstructive hypertrophic cardiomyopathy and approved Opdivo plus AVD for newly diagnosed advanced classical Hodgkin lymphoma in the EU. Together with positive Phase 3 data for the multiple myeloma candidate...

Alnylam Pharmaceuticals (ALNY) has come back into focus after the company outlined 2030 financial goals and reiterated AMVUTTRA’s central role, even as fresh headlines highlighted its AI partnership with Inceptive Nucleics. See our latest analysis for Alnylam Pharmaceuticals. Despite the recent AI collaboration and refreshed 2030 goals, Alnylam’s share price has been under pressure year to date, with a year to date share price return of down 25.6%. However, the 3 year total shareholder return...

Emerson Electric (EMR) is back in focus after announcing a collaboration with SiMa.ai to bring machine learning System on Chip technology into its industrial PCs, putting fresh attention on the stock’s Industrial AI ambitions. See our latest analysis for Emerson Electric. Emerson Electric’s recent Industrial AI partnership with SiMa.ai comes after a steady year of gains, with the share price up 4.86% year to date and a 1-year total shareholder return of 14.02%. The 3-year total shareholder...

AXIA Energia stock snapshot AXIA Energia (AXIA) has drawn attention after recent trading performance, with the stock at $9.83 and mixed short term returns, including a gain of 1.03% over the past day but pressure over the past month. See our latest analysis for AXIA Energia. Recent trading has been choppy, with the share price down 18.02% over the past 30 days and 16.55% over 90 days, yet the 1 year total shareholder return of 76.22% shows how strongly long term holders have been rewarded. If...

Recently, Zacks Investment Research upgraded Stock Yards Bancorp (SYBT) to a Rank #2 (Buy), citing an improved earnings outlook and upward-trending estimates. This shift in analyst view, combined with neutral short-term quantitative signals, highlights a changing perception of the bank’s earnings resilience. We’ll now examine how this Zacks Rank upgrade, tied to improved earnings expectations, reshapes Stock Yards Bancorp’s broader investment narrative. Outshine the giants: these 14...

What the Tuscaloosa resort announcement means for Travel + Leisure (TNL) Travel + Leisure (TNL) is extending its Sports Illustrated Resorts brand with a ground-up, mixed-use project in Tuscaloosa, Alabama, near the University of Alabama, tying year-round hospitality and residential offerings to a large college sports market. See our latest analysis for Travel + Leisure. Recent momentum has been building, with a 1-month share price return of 9.71% and a 1-year total shareholder return of...

Why Sotera Health is back in focus Goldman Sachs has initiated coverage of Sotera Health (SHC), just as the company reports first quarter 2026 earnings that topped revenue and profit expectations and gains clarity on Ethylene Oxide related legal exposures. See our latest analysis for Sotera Health. The recent 1 day share price return of 4.22% to US$16.53, alongside a 90 day share price return of 18.75% and 1 year total shareholder return of 34.39%, points to momentum building as investors...

In recent days, Quest Diagnostics has attracted favorable attention from Wall Street, with analysts issuing 9 buy and 9 hold ratings and no sell calls, reflecting confidence in its broad portfolio of diagnostic testing and healthcare services across the United States. This cluster of positive opinions highlights how Quest’s diversified offering and perceived financial resilience are shaping analyst views on its role in an evolving healthcare landscape. We’ll now examine how this upbeat...

Fox Corporation and the National Football League previously announced a multi-year agreement to bring an extensive slate of live NFL games and original football programming to Fox’s linear, streaming and ad-supported platforms in Mexico starting with the 2026 season. This expansion into Mexico deepens Fox’s relationship with premium live sports while broadening its reach across Latin American audiences and digital services like FOX One and Tubi. Next, we’ll examine how adding comprehensive...

Event context for ERock (EROC) ERock (EROC) is on investor radars after fresh attention on its modular power systems business for data centers, utilities, and commercial clients. The stock last closed at US$21.50 and has a market cap around US$4.71b. See our latest analysis for ERock. With year to date share price returns at 0.00%, the recent focus on ERock’s modular power systems is putting more weight on future execution and risk expectations than on past trading momentum. If this kind of...

Wondering whether Fastly at around US$18.63 is still offering value or if most of the opportunity is already priced in? This breakdown will help you frame the stock through a valuation lens. The share price has pulled back, with Fastly down 10.3% over the last week and 9.2% over the last month, even after a strong 82.8% year to date return and 130.6% return over the past year. These moves come as Fastly remains in focus for investors watching the broader software sector and reassessing risk...

VeriSign overview and recent share performance VeriSign (VRSN) has drawn investor attention recently, with the stock roughly flat over the past month, up about 20% in the past 3 months and 18% year to date. Over the past year, the total return stands at about 3%, while the 3 year and 5 year total returns are approximately 29% and 31%. These figures offer useful context before you look at earnings and valuation. See our latest analysis for VeriSign. While the share price is around $283.89...

Shareholders at nLIGHT's 2026 Annual Meeting voted against the board's proposed executive compensation plan. The failed "Say on Pay" vote signals clear pushback on how leadership at NasdaqGS:LASR is being rewarded. This outcome raises fresh questions around governance priorities and executive alignment with shareholder interests. nLIGHT, listed as NasdaqGS:LASR, develops high power semiconductor and fiber laser solutions for industrial, defense, and other applications. For investors...

If you are wondering whether Truist Financial's share price still offers value at current levels, the next step is to look closely at what that price actually implies. The stock recently closed at US$49.43, with returns of 2.7% over the past week, 0.7% over the past month, a small decline of 0.6% year to date, and gains of 26.9% over 1 year, 78.0% over 3 years, and 9.7% over 5 years. Recent coverage has focused on Truist Financial as a large U.S. bank stock that remains in focus for...

Zevra Therapeutics (ZVRA) is back in focus after requesting that a new patent for its approved Niemann Pick type C treatment MIPLYFFA be added to the FDA’s Orange Book, with the goal of extending exclusivity through 2041. See our latest analysis for Zevra Therapeutics. The Orange Book patent move has arrived alongside strong momentum, with Zevra’s share price delivering a 63.79% year to date return and a 31.22% 90 day share price return. The 3 year total shareholder return of 134.71%...

If you are wondering whether Fair Isaac at around US$1,225 per share looks expensive or attractive, the answer depends heavily on how you think about value in the first place. The stock has been volatile recently, with a 7 day move of around 2.1% lower, an 8.8% gain over the past month, a decline of 25.4% year to date, and a 31.4% decline over the last year, set against longer term gains of 52.8% over 3 years and 145.3% over 5 years. Recent coverage has focused on how Fair Isaac fits into...

Perrigo (NYSE:PRGO) announced the immediate resignation of CEO and President Patrick Lockwood-Taylor following a Board determination of conduct inconsistent with the company’s Code of Conduct and core values. The company stated the issue is unrelated to Perrigo’s operations or financial reporting. Board member Albert A. Manzone has been appointed Interim CEO while a comprehensive search for a permanent CEO is underway. Perrigo’s leadership change comes at a time when the stock has faced...

SailPoint (SAIL) has opened Q1 2027 with revenue of US$280.1 million, a loss of US$74.7 million in net income and basic EPS of US$0.13 loss, while the trailing twelve months show revenue of US$1.1 billion and a total EPS loss of US$0.28. Over recent quarters the company has seen revenue move from US$230.5 million in Q1 2026 to US$280.1 million in Q1 2027, alongside quarterly EPS losses in a range between US$0.42 and US$0.02. The latest print keeps the focus firmly on how quickly revenue...

Wondering whether Xylem's share price still reflects fair value, or if the recent moves have opened up a mispricing worth your attention. The stock recently closed at US$110.87, with a small 0.5% gain over the last 7 days, a 2.5% decline over the past month, and a year to date fall of 19.1% that leaves the 1-year return down 12.6% and the 3-year and 5-year returns at 3.8% and 0.3% respectively. Recent news coverage has focused on Xylem's role in the broader capital goods sector and ongoing...

Vitesse Energy, Inc. ( NYSE:VTS ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is usually set...

Investors who take an interest in Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) should definitely note that the CEO...

If you are wondering whether IES Holdings at around US$726 per share still offers value, or if most of the opportunity is already priced in, this article explains what the current price could mean for you. The stock has recently shown strong momentum, with returns of 3.0% over the last 7 days, 8.9% over the last 30 days, 78.5% year to date, 169.3% over 1 year, and a very large gain over 3 and 5 years. Recent coverage of IES Holdings has focused on its sharp share price performance and...